Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Authors
Publication date
23 November 2021
Publisher
'American Society of Hematology'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      ORA - Oxford University Research Archive

      redirect
      oaioai:ora.ox.ac.uk:uuid:32b367a7...
      Last time updated on 20/10/2022